Erbitux and Hearing loss - a phase IV clinical study of FDA data

Summary:

Hearing loss is reported as a side effect among people who take Erbitux (cetuximab), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Paclitaxel, and have Lung cancer - non-small cell.

The phase IV clinical study analyzes which people have Hearing loss when taking Erbitux. It is created by eHealthMe based on reports of 19,227 people who have side effects when taking Erbitux from the FDA, and is updated regularly.

What is Erbitux?

Erbitux has active ingredients of cetuximab. It is often used in cancer. eHealthMe is studying from 19,276 Erbitux users. Check the latest studies of Erbitux.

What is Hearing loss?

Hearing loss is found to be associated with 1,358 drugs and 2,384 conditions by eHealthMe. Check the latest studies of Hearing loss.

On Aug, 06, 2026

19,227 people reported to have side effects when taking Erbitux.
Among them, 20 people (0.1%) have Hearing loss.

Among these 20 people:

How long have people been on Erbitux when they have Hearing loss? *

What is the gender of people who have Hearing loss when taking Erbitux? *

female: 31.58 %
male: 68.42 %

What is the age of people who have Hearing loss when taking Erbitux? *

What are other drugs people take besides Erbitux? *

What are other side effects people have besides Hearing loss? *

Rashes (redness): 5 people, 25.00%
White Blood Cell Count Decreased: 4 people, 20.00%
Otitis Media (inflammation of the middle ear): 2 people, 10.00%
Aspartate Aminotransferase Increased: 2 people, 10.00%
Blister (small pocket of fluid within the upper layers of the skin caused by forceful rubbing (friction), burning, freezing, chemical exposure): 2 people, 10.00%
Blood Alkaline Phosphatase Increased: 2 people, 10.00%
Death: 2 people, 10.00%
Ear Discomfort: 2 people, 10.00%
Haematocrit Decreased: 2 people, 10.00%
Headache (pain in head): 2 people, 10.00%

What are the existing conditions these people have? *

Lung Cancer - Non-Small Cell (lung cancer): 4 people, 20.00%
Oral Cancer (mouth cancer): 3 people, 15.00%
Tongue Neoplasm Malignant Stage Unspecified: 2 people, 10.00%
Stroke (sudden death of a portion of the brain cells due to a lack of oxygen): 1 person, 5.00%
Rectosigmoid Cancer (cancer that originates in the rectum and sigmoid colon): 1 person, 5.00%
Oropharyngeal Cancer Recurrent (cancer of oropharynx reoccurs): 1 person, 5.00%
Oesophageal Adenocarcinoma (a cancer tumour of an epithelium in oesophagus): 1 person, 5.00%
High Blood Pressure: 1 person, 5.00%
Diabetes: 1 person, 5.00%
Colon Cancer Metastatic (cancer of colon spreads to other part of body): 1 person, 5.00%

* Approximation only. Some reports may have incomplete information.

Do you take Erbitux and have Hearing loss?

- Check whether Hearing loss is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Erbitux:

Erbitux (19,276 reports)

Hearing loss treatments and more:

Hearing loss (30,352 reports)

Browse all side effects of Erbitux:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hearing loss:

Hearing loss (1,358 drugs)

Browse all the conditions that are associated with Hearing loss:

Hearing loss (2,384 conditions)

Related publications that referenced our studies

Gupta SK, Shwetank B, "Reversible bilateral sensori-neural hearing loss due to olanzapine in a male suffering from bipolar affective disorder", Indian journal of pharmacology, 2014 Jan .
Gupta D, Shukla P, Bisht SS, Bhatt ML, Pant MC, Srivastava K, "Deep vein and artery thrombosis associated with cetuximab-based chemoradiotherapy", Indian journal of pharmacology, 2011 Jan .
Gupta SK, Shwetank B, "Reversible bilateral sensori-neural hearing loss due to olanzapine in a male suffering from bipolar affective disorder", Indian journal of pharmacology, 2014 Jan .
Gupta D, Shukla P, Bisht SS, Bhatt ML, Pant MC, Srivastava K, "Deep vein and artery thrombosis associated with cetuximab-based chemoradiotherapy", Indian journal of pharmacology, 2011 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on cetuximab (the active ingredients of Erbitux) and Erbitux (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.